You are here : Network » Registry for QLD » Member Details Little font Medium font Large font
Dr Don Gardiner FRSTMH
Dr Don Gardiner
The Queensland Institute of Medical Research logo


Laboratory Head
Malaria Biology Laboratory

The Queensland Institute of Medical Research
300 Herston Road, Herston, QLD 4029

Phone: (61) 7 33620432
Fax: (61) 7 3362 0104

Research interests

Molecular genetics of P. falciparum.



Ten Most Significant Publications

1. Gardiner DL, Hartas J, Currie B, Mathews JD, Kemp DJ, Sriprakash KS. Vir typing: A long PCR typing method for group A streptococci. PCR Methods and Applications 1995; 4: 288-293. (Now part of Genome Research - Impact Factor 10.256) Cited 59 times. Impact Factor N/A

2. Carapetis J, Gardiner DL, Currie B, Mathews J. Genetic characterization of multiple strains of group A streptococci in the skin sores of Aboriginal Australians. J Clin Micro 1995; 33 : 1471-1472.. Impact Factor 3.445. Cited 24 times

3. Gardiner DL, Sriprakash KS. Molecular epidemiology of impetiginous group A streptococci in Aboriginal Communities of northern Australia. J Clin Micro 1996; 34 : 1448-1452. Impact Factor 3.445. Cited 37 Times

4. Gardiner DL, Thomas, E., Cowman, AF., and Kemp, DJ. Clag9: a cytoadherence gene in Plasmodium falciparum essential for binding of parasitized erythrocytes to CD36. Proc Natl Acad Sci USA. 2000;97:4029-4033. Joint First Author. Impact Factor 9.643. Cited 50 times

5. Gardiner DL, Trenholme, KR, Holt, D., Thomas, E., and Kemp, DJ. Inhibition of Plasmodium falciparum clag9 gene function by antisense RNA. Mol. Biochem. Parasitol. 2000;110:33-41. Impact Factor 2.641. Cited 26 times

6. Hawthorne PL,, Trenholme KR , Skinner-Adams TS, Spielmann T, Fischer K, Dixon MWA, Ortega MA, Anderson KA, Kemp, DJ, Gardiner DL. A Novel Plasmodium falciparum Ring Stage Protein, REX is located in Maurer's Clefts. Mol. Biochem. Parasitol. 2004. 136:181-189. Impact Factor 2.641. Cited 12 times

7. Skinner-Adams TS, McCarthy JS, Gardiner DL, Hilton PM, Andrews KT. Antiretrovirals as Antimalarials. J. Infect. Dis. 2004;190:1998-2000.. Impact Factor. 5.563. Cited 22 times

8. Gardiner DL, Trenholme KR, Skinner-Adams TS, Stack CM and Dalton JP.. Over-expression of Leucyl Aminopeptidase in Plasmodium falciparum Parasites: Target for the Anti-Malaria Activity of Bestatin. J. Biol. Chem. 2006 Jan 20;281(3):1741-5. Impact Factor 5.808. Cited 5 times

9. Spielmann T, Hawthorne PL, Dixon MWA, Hannemann M, Klotz K, Kemp DJ, Klonis N, Tilley L, Trenholme KR, and Gardiner DL. A cluster of ring stage-specific genes linked to a locus implicated in cytoadherence in Plasmodium falciparum codes for PEXEL negative and PEXEL positive proteins exported into the host cell. Mol Biol Cell. 2006 Aug;17(8):3613-24. Impact Factor 6.562

10. Skinner-Adams TS, Lowther J, Teuscher F, Stack CM, Grembecka J Mucha A, Kafarski P, Trenholme KR, Dalton JP, Gardiner DL. Identification of phosphinate inhibitors directed against the Plasmodium falciparum M17 leucine aminopeptidase. J. Med. Chem. 2007. Nov 29;50(24):6024-6031. Impact Factor 5.115.

Currently Held Grants

1. 2004-2009 Named Investigator on ARC/NHMRC Network Grant. ARC/NHMRC Research Network for Parasitology. One of 50 named Investigators.

2. 2006-2008 Chief Investigator on Australian Research Council Discovery Project. Aminopeptidases involved in regulating the amino acid pool in malaria parasites. Chief Investigators Dalton JP, Gardiner DL, Trenholme KR. Partner Investigator Grembecka J. ARC Project. PD0666128

3. 2008- Program Director on National Institutes of Health (NIH) Roadmap Molecular Libraries and Imaging Initiative. High Through-Put Screening of Plasmodium falciparum Aminopeptidases. Principal Investigators. Gardiner DL, Dalton JP, Trenholme KR. 1R03MH082342-01A1.

4. 2008 Chief Investigator on Griffith Medical Research College Collaborative Grant. Targeting the Achilles Heel of Malaria. Isoleucine transport and Peptide Nucleic Acids. Principal Investigators Gardiner DL, Brown C, Trenholme KR.

5. 2008-2011 Chief Investigator. NHMRC Career Development Award Biomedical Level II.